IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS

PURPOSE: Our clinical trials shows the safety and clinical efficacy of Wilms’ tumor 1 (WT1) human leukocyte antigen (HLA) class I (Izumoto S et al. J Neurosurg. 2008) and class II (Tsuboi A et al. Cancer Immunol Immunother. 2019) peptide vaccination for recurrent malignant gliomas have been establis...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurooncol Adv
Main Authors: Kagawa, Naoki, Oji, Yusuke, Tsuboi, Akihiro, Hirayama, Ryuichi, Kijima, Noriyuki, Kinoshita, Manabu, Oka, Yoshihiro, Sugiyama, Haruo, Kishima, Haruhiko
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213306/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.080
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki